‹ ›
MYP_136251
← PREVIOUS NEXT → BACK
Basic Information
IB-367
Antimicrobial
Antimicrobial ▸ Antibacterial
Antimicrobial ▸ Antibacterial ▸ Anti-Gram-negative
Antimicrobial ▸ Antibacterial ▸ Anti-Gram-positive
Antimicrobial ▸ Antifungal
Immunology ▸ Inflammation modulation ▸ Anti-inflammatory
Standard
17 amino acids
C78H129N29O19S4
Standard
Sequence
RGGLCYCRGRFCVCVGR
Physicochemical Analysis
1905.30 Da
9.37
3.72
3.46
0.2188
0.24
0.30
-0.14
-7.18
57.06
0.1176
1490.00
1740.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
796.75
-9.00
35.0
27.0
61.0
130.0
2.0
16.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0356621 VERIFIED: YES
Provenance & Taxonomy
Sus scrofa [Animal]
Protegrin
9823
Structure & Mods
disulfide-constrained cyclic peptide [Cyclic]
canonical L-amino-acid peptide [L]
5-14, 7-12
Bio-Activity Profile
Antibacterial Antifungal Anti-inflammatory Anti-mucositis
S. sanguis (14)
4-64 μg/mL
MIC
PaperA phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leukoc. Res.(2004) PMID15120931 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/15120931/
RECORD: Rec_0360906 VERIFIED: YES
Provenance & Taxonomy
Sus scrofa [Animal]
Protegrin
9823
Structure & Mods
disulfide-constrained cyclic peptide [Cyclic]
canonical L-amino-acid peptide [L]
5-14, 7-12
Bio-Activity Profile
Antibacterial Antifungal Anti-inflammatory Anti-mucositis
Serratia marcescens (16)
16-256 μg/mL
MIC
PaperA phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leukoc. Res.(2004) PMID15120931 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/15120931/
RECORD: Rec_0370551 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
4
Bio-Activity Profile
Antimicrobial Antibacterial
methicillin-resistant Staphylococcus aureus
8 μg/mL
MIC
PMID10931444 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/10931444/
RECORD: Rec_0371661 VERIFIED: YES
Provenance & Taxonomy
Sus scrofa [Animal]
Protegrin
9823
Structure & Mods
disulfide-constrained cyclic peptide [Cyclic]
canonical L-amino-acid peptide [L]
5-14, 7-12
Bio-Activity Profile
Antibacterial Antifungal Anti-inflammatory Anti-mucositis
Acinetobacter calcoaceticus (4)
0.06-2 μg/mL
MIC
PaperA phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leukoc. Res.(2004) PMID15120931 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/15120931/
RECORD: Rec_0372589 VERIFIED: YES
Provenance & Taxonomy
synthetic construct based on Clinical trials [Synthetic]
Protegrin
32630
Structure & Mods
synthetic linear peptide [Linear]
canonical L-amino-acid peptide [L]
Amidation
Bio-Activity Profile
Antimicrobial
Pseudomonas aeruginosa 18 strains
1-8 μg/mL
MIC
PaperDesign of Protegrin-1 Analogs with Improved Antibacterial Selectivity. PMID37631261 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/37631261/
FIRST PREV 1 ... 9 10 11 12 13 NEXT LAST
Showing 5 records on this page · Page 11 of 13